Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mei Pharma Inc
(NQ:
MEIP
)
2.800
-0.040 (-1.41%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mei Pharma Inc
< Previous
1
2
3
4
Next >
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
November 12, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Fiscal Year End 2024 Cash Position
September 19, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
August 12, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Consider Strategic Alternatives
July 22, 2024
From
MEI Pharma, Inc.
Via
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
May 14, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
May 09, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
April 11, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
March 26, 2024
From
MEI Pharma, Inc.
Via
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
February 15, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
February 13, 2024
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
January 16, 2024
From
MEI Pharma, Inc.
Via
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
December 14, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
December 11, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
November 09, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
November 08, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
November 06, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
November 02, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
November 01, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Recommends Stockholders Not to Consent
October 17, 2023
From
MEI Pharma
Via
Business Wire
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
October 02, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
September 28, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
September 26, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
September 21, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
September 18, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
August 16, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Announces Results of Special Meeting of Stockholders
July 23, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
July 19, 2023
From
MEI Pharma, Inc.
Via
Business Wire
MEI Pharma Responds to Anson and Cable Car
July 18, 2023
From
MEI Pharma, Inc.
Via
Business Wire
Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc.
July 17, 2023
From
Anson Funds Management LP
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
